RNA binding motif protein 24Genealiases: RNPC6 · dJ259A10.1
Q-omics provides the consensus-scored RBM24 profile across patient tissues and cancer cell-line models. RBM24 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RBM24 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, RBM24 RNA expression shows 18,074 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, BLCA, and TGCT as cancer lineages where RBM24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBM24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBM24 survival associations across molecular data types. RBM24 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBM24 RNA expression–survival associations across cancer types. High RBM24 expression shows unfavorable associations in UVM, MESO, HNSC, BLCA and LGG, but favorable associations in BRCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RBM24 RNA expression.
This table summarizes RBM24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RBM24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBM24 shows lower tumor expression in BLCA, THCA, KICH and COAD and higher tumor expression in LIHC and KIRC. The BLCA box plot shows higher RBM24 RNA expression in normal versus tumor tissue (log2 FC = −3.612, t-test p < 0.001).
This table shows molecular features associated with RBM24 in patient tissues and cancer cell lines. In patient samples, RBM24 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RBM24 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and SOFT_TISSUE.
